Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients

Clinical Infectious Diseases

Volumn 47, Issue 2, 2008, Pages 296-297

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; INFECTION PREVENTION; LETTER; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; GANCICLOVIR; HUMANS; ORGAN TRANSPLANTATION;

EID: 46349104637     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/589577     Document Type: Letter

References (15)

1. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008; 46:732-40.
2. Arthurs S, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease andthe risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840-6.
3. Limaye A, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-52.
4. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-Week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81:1106-11.
5. Reischig T, Jindra P, Hes O, Svecova M, Kloboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2007; 7:1-9.
6. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134-43.
7. Singh N. Universal prophylaxis versus preemptive therapy for cytomegalovirus prophylaxis in organ transplant recipients. Clin Infect Dis 2001; 32:742-51.
8. Potena L, Holweg CT, Chin C. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus. Transplantation 2006; 82:398-405.
9. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187:1801-8.
10. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J 1999; 138:S469-72.
11. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositve donor allografts. Liver Transpl 2008; 14:240-2.
12. Kim DH, Won DI, Lee NY, et al. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation. Transplantation 2006; 81:101-8.
13. Scholz D, Arndt R, Meyer R. Evidence for an immunosuppressive activity of ganciclovir. Transplant Proc 1994; 26:3253-4.
14. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190:1908-12.
15. Kijpittayarit S, Deziel P, Eid AJ, Razonable RR. Primary cytomegalovirus disease after 5 years of antiviral prophylaxis. Transplantation 2006; 81:137-8.